Inflammatory Cardiomyopathy
Conditions
Keywords
ICM, myocarditis, cardiomyopathy, endomyocardial biopsy, immunosuppression
Brief summary
The aim of this study is to compare the effect of combined immunosuppressive therapy given on the top standard medical therapy of chronic heart failure according to current guidelines with standard medical therapy of chronic heart failure alone in patients with infammatory cardiomyopathy (ICM). Suitable subjects are characterized by EMB established presence of myocardial inflammation / negative polymerase chain reaction assay (PCR) findings of cardiotropic infectious agents and with varying duration of heart failure symptoms and left ventricular (LV) systolic dysfunction (phase A). Further, to compare the effect of two regimens of combined immunosuppressive therapy in these patients with ICM (phase B).
Interventions
DRUGCombination of prednisone and azathioprine
* Prednisone for a total of 90 days, with initial dose 1mg/kg/day p.o., given for 12 days and then tapered every 5 days for 5mg/day to the maintenance dose of 0.2mg/kg/day. The daily dose of Prednisone will be rounded to the nearest value divisible by 5. * Azathioprine for 100 days in total, with dose 1 mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25.
OTHERNo intervention
No intervention, only standard medical therapy
Sponsors
St. Anne's University Hospital Brno, Czech Republic
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Males and females aged 18 to 65 years at the time of signing the informed consent 2. Signing of the informed consent. 3. LV systolic dysfunction defined by ejection fraction less than/or equal 40% as assessed by echocardiography and symptoms of heart failure (minimum NYHA class II) lasting for at least 2 weeks at the time of randomization. This criterion also determines the inclusion of the study subjects in one of two substudies (CZECH-ICIT 1 or CZECH-ICIT 2). * LV systolic dysfunction (defined by ejection fraction less than/or equal 40%) and symptoms of heart failure (minimum NYHA class II) lasting 2 weeks to 6 months, with standard medical therapy of chronic heart failure given for at least 2 weeks - the subject fulfills criterion for inclusion in CZECH-ICIT 1 substudy * LV systolic dysfunction (defined by ejection fraction less than/or equal 40%) and symptoms of heart failure (minimum NYHA class II) lasting more than 6 months, with standard medical therapy of chronic heart failure given for at least 2 weeks - the subject fulfills criterion for inclusion in CZECH-ICIT 2 substudy 4. Positive immunohistochemistry finding of myocardial inflammation in endomyocardial biopsy (EMB). EMB must have been be performed no more than 6 weeks prior to the inclusion in the study. Positive immunohistochemistry EMB finding demonstrating myocardial inflammation is defined by the presence of at least 7/mm2 cluster of differentiation 3 (CD3) positive lymphocytes and/or at least 14 infiltrating leucocytes (LCA+ cells)/mm2 in the specimen. 5. The absence of infectious agent in EMB is defined by negative results of PCR testing of EMB specimens. PCR testing will be aimed to exclude the presence of enteroviruses (ECHO, coxsackie), adenoviruses, herpes viruses (herpes simplex virus (HSV-1), Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpes virus (HHV-6)), Borrelia burgdorferi and parvovirus B19. In the case of parvovirus B19, a negative PCR result will be considered when less than 500 viral copies/ug genomic DNA are detected. EMB must have been performed no more than 6 weeks prior to the inclusion in the study. 6. Negative blood pregnancy test in fertile females. 7. Usage of the effective method of contraception (hormonal or 2 barrier method of contraception)
Exclusion criteria
1. The presence of coronary artery disease, defined by angiographic findings of one or more coronary artery stenosis \> 50%, history of previous myocardial infarction and/or percutaneous or surgical myocardial revascularization. Coronary angiography must not have been performed more than 2 years before randomization into the study. 2. Permanent pacemaker including cardiac resynchronization therapy. 3. The presence of uncontrolled, persistent supraventricular tachyarrhythmia, with ventricular rate \> 120/min, lasting more than 1 week before EMB. 4. The presence of uncontrolled arterial hypertension, defined by blood pressure values \> 180mmHg (for systolic pressure) and/or 110mmHg (for diastolic pressure) lasting more than 3 months. 5. The presence of at least moderately hemodynamically significant primary valvulopathy or congenital heart disease (apart from patent foramen ovale and non-significant atrial septal defect). 6. Previous heart valve surgery (replacement or reconstruction) or surgical correction of congenital heart disease. adu. 7. A history of cytostatic therapy or radiotherapy. 8. Alcoholism defined as ethanol intake \>90 g/day. 9. The presence of uncontrolled endocrine of metabolic disorder. 10. Gravidity and lactation. 11. Known hypersensitivity to investigational drugs. 12. All contraindications of immunosuppressive therapy according to Summary of product characteristics (SmPC) of both investigational medicinal products: untreated systemic infection, poorly manageable diabetes mellitus, osteoporosis, florid gastric or duodenal ulcer, uncontrolled arterial hypertension, history of malignant disease with oncological treatment finished less than 5 years, proven immunodeficiency, renal of hepatic insufficiency (serum creatinine \> 200 µmol/l; alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) activity greater than three times the standard), leukocytopenia (leucocytes less than 4 x 10 9/l), thrombocytopenia (platelets less than 100 x 10 9/l), anemia (hemoglobin concentration less than 100 g/l).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| comparison of the change in LV ejection fraction | baseline and in 12 months after the initiation of immunosuppressive therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| comparison of the change of LV end-diastolic and end-systolic diameters | baseline and in 12 months after the initiation of immunosuppressive therapy | — |
| comparison of the change of New York Heart Association (NYHA) class | baseline and in 12 months after the initiation of immunosuppressive therapy | — |
| comparison of total mortality | baseline and in 12 months after the initiation of immunosuppressive therapy | — |
| comparison of the combined end-point | baseline and in 12 months after the initiation of immunosuppressive therapy | combined end-point (death from cardiac reasons, heart transplantation, hospitalization for heart failure, successful resuscitation for cardiac arrest and adequate implantable cardioverter-defibrillator (ICD) shock for ventricular tachycardia or fibrillation |
| comparison of the change in the number of infiltrating inflammatory cells in EMB | baseline and in 12 months after the initiation of immunosuppressive therapy | — |
Countries
Czechia
Outcome results
None listed